Europe Pharmaceutical Logistics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Europe Pharmaceutical Logistics Market Trends and Insights

Growth of Biologics & Temperature-Sensitive Drugs

Biologics, cell, and gene therapies are expanding faster than the broader life-sciences sector, with biopharma volumes growing at double-digit rates and pushing the share of cold-stored medicines to 35% of total pharmaceutical value in 2022. Nordic manufacturers such as Novo Nordisk and Fujifilm Diosynth are investing over DKK 70 billion (USD 10.36 billion) in capacity, creating fresh demand for GDP-certified storage and -80°C transport lanes. To curb cost and emission pressures, shippers are pivoting from air to ocean freight when lead-time and product risk profiles allow. Advanced therapy medicinal products (ATMPs) now drive ultra-cold packaging innovations, while Sweden’s 146 CAR-T treatments in 2024 highlight the scale-up of personalized medicine workflows.

Surge in E-commerce/OTC Fulfillment Volumes

Europe’s e-pharmacy sector is projected to expand by 65% by 2028 as Germany, the UK, and France roll out e-prescription networks and AI-based order routing. Growth in home health services for an aging population requires time-defined, temperature-controlled last-mile deliveries. Logistics specialists such as Eurotranspharma have launched dedicated line-haul and city-distribution fleets to ensure GDP compliance down to the patient doorstep. Counterfeit risk and patchwork rules for controlled substances continue to constrain cross-border volume flows, but harmonized data-sharing platforms are mitigating compliance burdens.

Stricter EU GDP & Serialization Enforcement

Updated GDP guidelines effective January 1 2025 eliminate pandemic-era certificate extensions and restore on-site audits, forcing operators to modernize quality-management systems GMP^{[2]“Half of European truck operators can’t expand due to driver shortages,” IRU, iru.org} . Italy’s February 9 2025 serialization deadline is galvanizing late-stage system upgrades across Southern Europe. The UK’s Windsor Framework introduces “UK Only” labels, adding cross-border documentation layers that ripple through warehousing and transport contracts.

Outsourcing to 3PL/4PL Pharma-Specialists

Rising product complexity is nudging shippers toward external logistics partnerships. Major 3PLs have responded with GDP-certified mega-hubs, predictive control-tower platforms, and GDP-trained cold chain crews. Providers such as DHL and CEVA have committed multi-billion-euro capex programs to upgrade European health-care networks, while clinical-trial sponsors rely on niche specialists for “vein-to-vein” traceability in cell-therapy programs.

High Energy & Refrigerant Costs for Cold-Chain Assets

EU F-gas quota curbs and a multi-year surge in R452A prices up to 1,000% since 2014 are inflating operating outlays for reefer fleets^{[3]“Guidelines on Good Distribution Practice,” European Commission, gmp-compliance.org}. OEMs such as Carrier Transicold have levied surcharges from January 2025 and plan lower-GWP blends later in the year. Power-price volatility, despite stabilizing LNG imports, is still eroding margins, spurring investments in solar-assisted depots and hydrocarbon refrigerants^{[4]“High GWP refrigerants face soaring prices,” Green Cooling Initiative, green-cooling-initiative.org}.

Driver Shortages and Road-Capacity Constraints

Europe lacks more than 500,000 qualified heavy-vehicle drivers today, a gap projected to widen to 745,000 by 2028, limiting fleet utilization and inflating wages. Germany faces the steepest deficit, with only 2.6% of its driver cohort younger than 25 years. Congestion on aging motorway corridors and rising tolls linked to CO₂ classes further curb productivity. Modal diversification can alleviate but not fully offset the labor crunch.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Service Type: Transportation Dominance Drives Infrastructure Investment

Transportation services accounted for 59.32% of Europe pharmaceutical logistics market share in 2025, underscoring the sector’s dependence on road, air, ocean, and rail capacity. Value-added services, though a smaller pool, are forecast to contribute USD 14.79 billion to Europe pharmaceutical logistics market size by 2031, expanding at 4.88% CAGR as shippers seek batch-level tracking, regulatory documentation, and kitting support. Road haulage moves the lion’s share of medicines, yet EU toll hikes pegged to CO₂ classes are tightening margins and accelerating fleet renewal toward battery-electric and hydrogen drivelines. Airfreight operators are retrofitting unit-load devices to meet ReFuelEU mandates for 2% sustainable aviation fuels from 2025, while ocean carriers leverage FuelEU Maritime rules to pitch lower-carbon temperature-controlled containers.

Automation and digitalization define future warehousing value creation. Fully robotized Nordic depots can move 1,000 pallets per hour, reducing human error and improving batch traceability. Meanwhile, the EUR 7 billion EU infrastructure package is expanding rail freight capacity, with the Lyon-Turin tunnel slated to boost inter-alpine pharmaceutical flows once operational. Overall, the service mix is shifting from pure transport toward integrated, temperature-controlled orchestration, allowing operators to lock-in multi-year contracts and stabilize revenue.

By Mode of Operation: Cold-Chain Complexity Reshapes Service Models

Cold-chain solutions held 57.42% of Europe pharmaceutical logistics market size in 2025 due to the proliferation of biologics, vaccines, and precision therapies. However, non-cold-chain lanes will register a 4.44% CAGR to 2031 as reformulated room-temperature-stable biologics and OTC categories gain traction. Heatwaves and storms in 2024 exposed vulnerabilities in older reefer fleets, prompting accelerated rollout of solar-powered depots and next-generation eutectic plates. Logistics leaders such as CEVA project reusable packaging penetration to reach 70% by 2030, lowering waste and carbon budgets.

Ultra-cold shipments for cell and gene therapies remain capacity-constrained east of Germany. Cold Chain Technologies’ new Breda plant adds multi-format shipper production and cuts lead times across the Benelux and CEE by two days. Non-cold-chain services, while operationally less complex, must still meet GDP traceability mandates, leading to increased adoption of IoT sensors even for ambient cargo.

By Product Type: Prescription Drugs Anchor Growth While Vaccines Accelerate

Prescription medicines retained the largest 31.35% tranche of Europe pharmaceutical logistics market share in 2025, reflecting high chronic-care volumes and established procurement channels. Vaccines and blood products, stewarded by expanding immunization programs and pandemic-preparedness stockpiling, will outpace all other categories at 5.53% CAGR through 2031. Biologics and biosimilars demand specialized handling, driving cold-chain capex throughout Western Europe. Germany’s pharmaceutical market is forecast to add USD 28 billion between 2024 and 2032 on the back of biopharmaceutical plant expansions and personalized therapy adoption.

Clinical trial materials face new labeling freedoms under the Clinical Trial Regulation, which allows hospital relabeling to cut waste but raises chain-of-custody complexity. Cell and gene therapies require vein-to-vein orchestration, and medical centers are ramping cryopreservation and RFID-tagging capacity to manage donor-patient pairings. Medical devices, spurred by EUDAMED rollout in 2026, will call for harmonized UDI data flows that integrate with logistics control towers.

Geography Analysis

Germany generated 16.62% of Europe pharmaceutical logistics market size in 2025, leveraging its 13,000 km motorway grid and status as a manufacturing nucleus. Toll extensions to vehicles over 3.5 tons from July 2024 add cost pressure but accelerate efficiency drives in fleet telematics and alternative fuels. The United Kingdom contends with chronic drug shortages and higher import paperwork despite Windsor Framework mitigations, which streamline licensing yet impose UK-only labeling for mainland trade. The Netherlands exploits Rotterdam’s cold-chain port cluster and Schiphol’s Pharma Gateway corridor to attract high-value biologic traffic.

Poland, the fastest growing geography at a 4.73% CAGR to 2031 is modernizing motorway and rail hubs to become a CEE consolidation point. Italy, facing its February 2025 serialization deadline, channels capex into track-and-trace IT ahead of regulatory cut-offs. Spain links GDP-compliant logistics incentives to CO₂-indexed toll reform, while Sweden leads in battery-electric truck adoption, supported by Eurovignette tariffs pegged to emissions from March 2025. Rest-of-Europe markets, particularly Hungary and Romania, offer greenfield opportunities for ultra-cold storage networks where incumbents are scarce.

Regulatory Landscape

Pharmaceutical logistics in Europe is governed by the EU quality framework for medicinal products, with mandatory Good Distribution Practice (GDP) as the core operating standard for storage, handling, and transport under the EU GDP guidelines (2013/C 343/01). Wholesale distributors operating in the EEA must hold a wholesale distribution authorization issued by the national competent authority in the country of activity, and GDP compliance is central to maintaining these authorizations. This shapes audit readiness, documentation, and the qualification of transport lanes and subcontractors.

In 2026, the EU advanced a major legislative reset via the pharmaceutical reform package published on 6 March 2026, setting a transition period of about 24 months (2026-2028) for Member States to update national laws and for EMA and national authorities to develop implementing guidance. In July 2026, the European Medicines Agency (EMA) updated its Q&A guidance covering GMP and GDP topics (EMA/INS/GMP/161750/2026), reinforcing that operators must keep quality systems current as interpretations and expectations evolve alongside the reform agenda.

Value Chain Analysis

The European pharmaceutical logistics value chain typically runs from manufacturers (biopharma, vaccines, medical technology) through wholesalers and specialized logistics providers to hospitals, pharmacies, and increasingly patient-direct channels. Execution relies on freight forwarders and carriers (road, air, ocean, and rail), airport and ground-handling operators for temperature-controlled air cargo, and packaging, data, and monitoring technology providers (thermal packaging, IoT sensors, track-and-trace, and quality management systems) to maintain GDP compliance across multi-country movements.

GDP requirements and cross-border complexity drive a layered services structure where warehousing and distribution centers integrate secondary packaging, labeling, kitting, returns, and compliance documentation alongside storage. Network-led models are expanding to combine local execution with harmonized standards, illustrated by LOXXESS establishing PharmaXnet Europe GmbH in April 2026 as a GDP-certified pharmaceutical logistics network using qualified local partners. Capacity is concentrating in multi-temperature hubs to serve biologics and advanced therapies, with DHL Group expanding its Florstadt Health Logistics campus in Germany in May 2025 by 100,000 square meters and adding capacity for over 140,000 pallets.

Market Opportunities and Future Outlook

Multi-temperature and ultra-cold infrastructure remains a visible whitespace, particularly where therapy mix is shifting toward biologics and advanced therapies while capacity is uneven across countries. Recent capacity adds show where investment is flowing and where adjacent nodes can be built out: Movianto expanded its Aalst, Belgium site in June 2026, doubling temperature-controlled pallet positions from 14,000 to 25,000 across ambient, chilled, frozen, and ultra-cold, and Frankfurt Cargo Services opened a new CEIV- and GDP-certified Pharma Center at Frankfurt Airport in May 2026, quadrupling temperature-controlled handling capacity. These moves support opportunities for additional GDP-certified satellite depots, qualified lane development (including ultra-cold packaging and validation services), and control-tower orchestration tied to major hubs.

Policy initiatives aimed at supply resilience create further whitespace in Central and Eastern Europe for compliant storage, distribution, and value-added services close to reshoring and regional manufacturing programs. The European Commission proposed the Critical Medicines Act in March 2025 to incentivize manufacturing relocation to the EU, and the EU reached political agreement in December 2025 to modernize pharmaceutical legislation with measures targeting shortages and supply chain functioning. Operators that can combine GDP-grade execution with regulatory documentation, serialization-ready processes, and cross-border customs capabilities are positioned to capture incremental outsourcing as shippers rebalance networks toward resilience-focused footprints.